Reumatoloxía
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (61)
2024
-
18F-FDG-PET/CT Scan for Detection of Large Vessel Involvement in Giant Cell Arteritis: Arteser Spanish Registry
Journal of Clinical Medicine, Vol. 13, Núm. 20
-
Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis
European Journal of Internal Medicine, Vol. 129, pp. 78-86
-
Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register
RMD open, Vol. 10, Núm. 1
-
SER recommendations on treatment of refractory Behçet's syndrome
Reumatologia Clinica, Vol. 20, Núm. 4, pp. 204-217
-
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort
Lupus Science and Medicine, Vol. 11, Núm. 1
2023
-
Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients
Seminars in Arthritis and Rheumatism, Vol. 58
-
Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)
Seminars in Arthritis and Rheumatism, Vol. 58
-
Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients
Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 829-836
-
Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)
Seminars in Arthritis and Rheumatism, Vol. 61
-
The complex HLA-E-nonapeptide in Behçet disease
Frontiers in Immunology, Vol. 14
2022
-
Biologic therapy in refractory neurobehçet's disease: a multicentre study of 41 patients and literature review
Rheumatology (Oxford, England), Vol. 61, Núm. 11, pp. 4427-4436
-
Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
Therapeutic Advances in Musculoskeletal Disease, Vol. 14
2021
-
Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?
Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563
-
Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study
European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382
-
Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review
Therapeutic Advances in Musculoskeletal Disease, Vol. 13
2020
-
Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
Lupus, Vol. 29, Núm. 12, pp. 1556-1565
-
Development of an application for mobile phones (App) based on the collaboration between the Spanish Society of Rheumatology and Spanish Society of Family Medicine for the referral of systemic autoimmune diseases from primary care to rheumatology
Reumatologia Clinica, Vol. 16, Núm. 5, pp. 373-377
-
Expert Recommendations on the Interleukin 6 Blockade in Patients with Rheumatoid Arthritis
Reumatologia Clinica, Vol. 16, Núm. 4, pp. 272-281
-
Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children
Pediatric Rheumatology, Vol. 18, Núm. 1
-
Fracture risk assessment in the general population in Spain by FRAX® algorithm. EPISER2016 study
Medicina Clinica, Vol. 154, Núm. 5, pp. 163-170